Health BMS Pays $100M for Next-Gen Orum Therapeutics ADC for Blood Cancers January 17, 2024 146 TelecomApril 3, 2026Democrat rips Polymarket for taking bets on fate of US pilot shot down over Iran TelecomApril 3, 2026A third of Americans planning to invest in high-risk, speculative assets: Study TelecomApril 3, 2026Anthropic launches new corporate PAC to ramp up election spending TelecomApril 3, 2026FBI labels data breach ‘major incident,’ notifies Congress TelecomApril 3, 2026Palantir-linked campaign donations put Democrats in tight spot Bristol Myers Squibb is expanding its scope in cancer by acquiring rights to a Phase 1-ready Orum Therapeutics program that brings a new twist to antibody drug conjugates. The deal is the latest business development move in the hot field of ADCs. Prime Plus Facebook Twitter Pinterest WhatsApp SportsApril 4, 2026Browns’ Shedeur Sanders Gets Surprising Update From Insider Sports Victor Wembanyama’s Playing Status Confirmed for Spurs-Nuggets April 4, 2026 Sports Detroit Pistons Make Tobias Harris Announcement vs 76ers April 4, 2026 Sports Jets Firmly Put on Notice Weeks Before NFL Draft April 4, 2026
